212 - Innovative Device for Percutaneous Biopsy Tract Closure: A Prospective Evaluation of Safety and Efficacy

Tuesday, April 14, 2026

3:45 PM - 3:54 PM ET

Presenting Author(s)

FK

Francis Kang, MD

Attending Physician
Rutgers Robert Wood Johnson Medical School, United States

Author/Co-author(s)

SB

Sumit Baral, MD

Attending Physician
Robert Wood Johnson University Hospital, United States
WC

Wayne Colizza, MD

Attending Physician
Robert Wood Johnson University Hospital, United States
JK

Joshua Kornblum, DO

Resident physician
Robert Wood Johnson University Hospital, United States
AK

Aleksander Kubiak, MD

Attending Physician
Robert Wood Johnson University Hospital, United States
IL

Ilya Livshits, MD

Attending Physician
Robert Wood Johnson University Hospital, United States
IM

Issam Moubarak, MD

Clinical Associate Professor
Rutgers Robert Wood Johnson Medical School, United States
SR

Shayan Rashid, MD

Clinical Assistant Professor
Rutgers Robert Wood Johnson Medical School, United States
SR

Sudipta Roychowdhury, MD

Attending Physician
Rutgers-Robert Wood Johnson Medical School, United States
Ali Saifuddin, MD

Resident
Rutgers, Robert Wood Johnson Medical School, United States
Sri Hari Sundararajan, MD

Assistant Professor of Radiology, Attending Physician of Neurointerventional Radiology, Interventional Radiology, and Diagnostic Neuroradiology
University Radiology Group / Robert Wood Johnson Universitu Hospital / St. Peter’s University University Hospital, United States
HW

Haokang Wei, MD

Resident physician
Robert Wood Johnson University Hospital, United States
JW

Joshua Wilkes, MD

Clinical Instructor
Rutgers Robert Wood Johnson Medical School, United States

Purpose: The purpose of this study was to prospectively evaluate the clinical safety and efficacy of a novel percutaneous biopsy tract closure device. This single-use, battery-powered electrocautery tool enables physicians to proactively achieve hemostasis at the source by sealing the biopsy channel from within the guide needle. This innovative approach is designed to enhance patient safety and procedural efficiency by providing a previously unavailable level of control and assurance.

Materials and Methods: A prospective, single-institutional study was conducted on 109 patients who underwent percutaneous biopsy followed by tract closure with the device. 12 interventional radiologists with varying levels of experience performed the procedures. The patient cohort had a median age of 62 (range, 2–87). Biopsies were performed in both inpatient (37.6%) and outpatient (62.4%) settings. The biopsies targeted the kidney (30 cases, including 8 tumors), liver (52 cases, including 43 tumors), and a diverse "other" category (27 cases, including 24 tumors) comprising masses in the lung, tongue, retroperitoneum, intraperitoneum, adrenal gland, chest wall, lytic osseous, and transplant pancreas.

Results: Among the 109 biopsies, 6 (5.5%) biopsy-related complications were observed. No complications were directly attributable to the device itself. Complications included 0.0% for liver biopsies (0 out of 52), a 13.3% for renal biopsies (4 out of 30), and a 7.4% for the "other" category (2 out of 27). The 6 complications included 4 mild perinephric hemorrhages that resolved without intervention, 1 small pneumothorax that did not require chest tube placement, and 1 retroperitoneal hemorrhage that necessitated angiogram and embolization. Only 1 patient in the entire cohort required an overnight hospital stay.

Conclusion: This prospective evaluation demonstrates that the innovative percutaneous biopsy tract closure device is both safe and effective across a wide array of challenging and diverse anatomical locations. The low overall complication rate of 5.5%, a major complication rate of just 0.9%, and the complete absence of complications in the liver biopsy cohort suggest the device's hemostatic capabilities are superior to existing methods. The ability to effectively seal the biopsy channel from within enhances patient safety and provides a high level of control. These results, coupled with the high rate of outpatient discharges, indicate that this device can significantly improve procedural efficiency and patient outcomes, positioning it as a new standard of care for percutaneous biopsies.